Nymox Reports Third Quarter 2013 Financial Results
November 14 2013 - 10:15AM
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its
financial results for the third quarter of 2013. Nymox reported a
net loss of $1,020,387, or $0.03 per share, for the quarter and
$3,591,682, or $0.11 per share, for the nine months ended September
30, 2013, compared to $1,245,563, or $0.04 per share, for the
quarter and $4,813,666, or $0.15 per share, for the nine months
ended September 30, 2012. The decrease in net losses in 2013
compared to 2012 is related to reductions in many areas of
expenditures mainly due to a reduction in clinical trial
expenditures as the NX-1207 studies near completion.
Revenues from sales amounted to $458,320 for the nine months
ended September 30, 2013, compared to $319,837 for the same period
in 2012. Additionally, for the nine months ended September 30, 2012
and 2011, amounts of $1,963,200 respectively were recognized as
revenue relating to the upfront payment received from Recordati in
December 2010. The weighted average number of common shares at
September 30, 2013 was 34,006,597, compared to 33,115,780 at
September 30, 2012.
Nymox Pharmaceutical Corporation is engaged in the research and
development of therapeutics and diagnostics, with a particular
emphasis on products targeted for the unmet needs of the aging
population. The Company's new drug for benign prostatic hyperplasia
(BPH) is in Phase 3 development in the U.S. and Europe. The
Company's candidate drug for prostate cancer is currently in Phase
2 testing in the U.S. Currently Nymox has three products on the
market, and a healthy pipeline of drug and diagnostic products. The
Company also has several hundred patents and patent
applications.
More information about Nymox is available at www.nymox.com,
email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements"
as defined in the United States Private Securities Litigation
Reform Act of 1995 that involve a number of risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and the actual results and future events could
differ materially from management's current expectations. Such
factors are detailed from time to time in Nymox's filings with the
United States Securities and Exchange Commission and other
regulatory authorities.
CONTACT: Roy Wolvin
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2024 to May 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From May 2023 to May 2024